Apr 18 2025 This Week in Cardiology
Episode description
The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I FAME 3 at Five Years
Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4
- Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
- Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770
- 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057
II TAVR in Low-Risk Patients at 5 years
5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients
- EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004
- EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428
- PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447
- NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606
III The Matter of Pacemakers After TAVI
- JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028
- Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals
IV Mavacamten Looks to Have Specific Indications
- EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link
- VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050
- BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/
FINAL THOUGHTS
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net